New Base Revlimid is used in follicular lymphoma December 25, 2017 Source: Sina Pharmaceutical On December 21, Celgene announced the failure of Revlimid (lenalidomide) combined with Baixu Rituxan (rituximab) to treat patients with untreated follicular lymphoma in the third phase, and the price of Celgene shares per share The plunge exceeded 5 percentage points. The clinical phase III study, called RELEVANCE, compared the efficacy and safety of Revlimid+Rituxan therapy with standard therapy rituximab+ chemotherapy. In this study, patients were given this combination therapy and then received Rituxan maintenance therapy. The trial data showed that Revlimid+Rituxan did not achieve superior results in 120 weeks compared to the current standard therapy in terms of the combined primary endpoint of complete response or unrecognized complete response and for the endpoint of progression-free survival. The company noted that further analysis of the data is underway and will be announced at future medical conferences. The RELEVANCE trial is the first post-clinical study of chemotherapy-free drugs compared to standard chemotherapy regimens in patients who have not previously received follicular lymphoma, and is referred to as a milestone by Gilles Salles, president of the Lymphoma Research Association. Jay Backstrom, the chief medical officer of New Base, said: "The company will continue to advance its 'wide range of new therapeutic lines' to bring new standard treatment options for the treatment of patients with lymphoma." However, Backstrom did not indicate whether the company plans to continue. Develop a combination of treatments for this particular indication. Follicular lymphoma is one of the most common forms of slow growth (inertness) in non-Hodgkin's lymphoma (NHL) and is difficult to cure once it recurs. It accounts for about one-third of all NHL patients. Newfound's blood cancer drug Revlimid has not been approved for the treatment of follicular lymphoma. The drug was approved in 2013 for the treatment of patients with hepatic lymphoma who have relapsed or progressed after prior treatment (one of them included bortezomib). In November 2017, the US FDA approved gazyva® (obinutuzumab) in combination with chemotherapy, followed by gazyva alone for the treatment of patients with untreated advanced follicular lymphoma (stage II heavy-duty, stage III, IV). Xinji is conducting clinical research in a variety of lymphoma patients, including the ongoing clinical IIIb MAGNIFY study of Revlimid and Rituximab in the treatment of marginal zone lymphoma, and for relapsed/refractory inert non-Hodgkin AUGMENT study of lymphoma treatment. Ian Somaiya, an analyst at BMO Capital, believes that although the RELEVANCE study failed, it will not have any impact on the AUGMENT study. (Sina Pharmaceutical Compilation / David) Article, image reference source: Celgene Crashed After Follicular Lymphoma Regimen Failed Phase III Acid-Base Balance of Medicine,Acid-Base Balance,Calcium Gluconate Injection,Finished Pharmaceutical Product,Acid-Base Balance Agent NOUVASANT GROUP LTD. , https://www.nouvasant.com
